Cellular Immunology, Год журнала: 2024, Номер 407, С. 104898 - 104898
Опубликована: Ноя. 28, 2024
Язык: Английский
Experimental Hematology and Oncology, Год журнала: 2024, Номер 13(1)
Опубликована: Авг. 5, 2024
Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.
Язык: Английский
Процитировано
11
Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12
Опубликована: Окт. 3, 2024
Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy, particularly with the success of CAR-T cells in treating hematologic malignancies. However, have limited efficacy against solid tumors. To address these limitations, CAR-macrophages (CAR-Ms) leverage innate properties macrophages specificity and potency CAR technology, offering a novel promising approach to cancer immunotherapy. Preclinical studies shown that CAR-Ms can effectively target destroy tumor cells, even within challenging microenvironments, by exhibiting direct cytotoxicity enhancing recruitment activation other immune cells. Additionally, favorable safety profile their persistence tumors position as potentially safer more durable therapeutic options compared This review explores recent advancements including engineering strategies optimize anti-tumor preclinical evidence supporting use. We also discuss challenges future directions developing therapies, emphasizing potential revolutionize By harnessing unique macrophages, offer groundbreaking overcoming current limitations cell paving way for effective sustainable treatments.
Язык: Английский
Процитировано
5
Biomedicines, Год журнала: 2025, Номер 13(2), С. 264 - 264
Опубликована: Янв. 22, 2025
Background: Chimeric antigen receptor (CAR) T cell therapy has shown significant promise in treating hematological malignancies, yet its application solid tumors, particularly those expressing the epidermal growth factor (EGFR), remains limited. This study investigates potential of CAR-engineered peripheral blood mononuclear cells (PBMCs) as a novel adoptive against EGFR-positive cancers. Methods: Lentiviral transduction at an MOI 50 was performed to generate specific anti-EGFR second generation CAR-effector cells. The transduced PBMCs were stimulated with cytokines and CD3/CD28 beads enhance their proliferation activation. Flow cytometric real-time analysis various effector-to-target ratios explore cytotoxic CAR-PBMCs. Results: CAR-PBMCs exhibited improved targeting cytotoxicity cancer lines MDA-MB-468 SK-BR-3, compared untransduced controls, unsignificant effects on allogeneic PBMCs. Conclusion: hold considerable therapeutic strategy for warranting further clinical investigation.
Язык: Английский
Процитировано
0
Current Research in Translational Medicine, Год журнала: 2024, Номер 73(1), С. 103488 - 103488
Опубликована: Дек. 4, 2024
Язык: Английский
Процитировано
2
Cellular Immunology, Год журнала: 2024, Номер 407, С. 104898 - 104898
Опубликована: Ноя. 28, 2024
Язык: Английский
Процитировано
0